Salivary gland toxicity from radiopharmaceutical therapy—particularly from alpha-emitting therapies like 225 Ac-PSMA—is a critical dose-limiting side effect, often leading to debilitating dry mouth.
Figure 1. Salivary gland protection with botulinum toxin and scopolamine during tandem PSMA-targeted radioligand therapy. NEW ORLEANS— A dual-protective approach using botulinum toxin (Botox) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results